Associated Papers
Whole-exome profiles of inflammatory breast cancer and pathological response to neoadjuvant chemotherapy.
Bertucci F et al.
Journal of Translational Medicine, 2024
39465437 (PubMed )
Supplement: 12967_2024_5790_MOESM2_ESM.xlsx › Table_S2
Mutational landscape of inflammatory breast cancer.
Bertucci F et al.
Journal of Translational Medicine, 2024
38637846 (PubMed )
Supplement: 12967_2024_5198_MOESM2_ESM.xlsx › Table_S2
Mono- and biallelic germline variants of DNA glycosylase genes in colon adenomatous polyposis families from two continents.
Olkinuora AP et al.
Frontiers in Oncology, 2022
36387175 (PubMed )
Supplement: Table_7.xlsx › Table_S7
Whole-exome sequencing in a patient with synchronous triple primary malignancies involving lung cancer: a case report.
Li D et al.
Precision Clinical Medicine, 2020
35692627 (PubMed )
Supplement: pbaa019_supplemental_file.zip › Supplementary_table_2.xlsx › Supplementary_table_1
Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors.
Ahlborn LB et al.
Oncotarget, 2018
30220966 (PubMed )
Supplement: oncotarget-09-32570-s003.xlsx › Sheet1
Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E.
Antonello ZA et al.
Oncotarget, 2017
29156680 (PubMed )
Supplement: oncotarget-08-84743-s004.xls › Sheet1
Select a paper to view details